MedPath

Retinset SL

Ownership
Private
Employees
-
Market Cap
-
Website

Safety of Bosentan in Type II Diabetic Patients

Phase 1
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Placebo
Drug: Bosentan
First Posted Date
2019-08-28
Last Posted Date
2023-02-16
Lead Sponsor
Retinset SL
Target Recruit Count
22
Registration Number
NCT04068272
Locations
🇪🇸

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

🇪🇸

IOBA, Valladolid, Spain

© Copyright 2025. All Rights Reserved by MedPath